PCN270 AVAILABILITY OF EARLY PREVENTION AND TARGETED THERAPY FOR BRCA-ASSOSIATED PATIENTS WITH BREAST AND/OR OVARIAN CANCER
نویسندگان
چکیده
منابع مشابه
Targeted Therapy for Breast Cancer Prevention
With a better understanding of the etiology of breast cancer, molecularly targeted drugs have been developed and are being testing for the treatment and prevention of breast cancer. Targeted drugs that inhibit the estrogen receptor (ER) or estrogen-activated pathways include the selective ER modulators (tamoxifen, raloxifene, and lasofoxifene) and aromatase inhibitors (AIs) (anastrozole, letroz...
متن کاملBreast and ovarian cancer in relatives of cancer patients, with and without BRCA mutations.
BACKGROUND First-degree relatives of patients with breast or ovarian cancer have increased risks for these cancers. Little is known about how their risks vary with the patient's cancer site, carrier status for predisposing genetic mutations, or age at cancer diagnosis. METHODS We evaluated breast and ovarian cancer incidence in 2,935 female first-degree relatives of non-Hispanic White female ...
متن کاملEffectiveness of trastuzumab as adjuvant therapy in patients with early stage breast cancer: A systematic review and meta-analysis
Background: Trastuzumab in combination with chemotherapy has long been established as a standard treatment for HER2-positive patients in early stage breast cancer (BC). The present study aimed at assessing the effectiveness of trastuzumab adjuvant therapy in early stage BC in overall survival (OS) and disease-free survival (DFS). Methods: A systematic review and meta-analysis was ...
متن کاملBRCA Genetic Testing for Patients With and Without Breast Cancer
Of the more than 200,000 breast cancers diagnosed annually in the United States, 5-10% are associated with obvious hereditary predisposition, which is mostly related to autosomal dominant mutations of the BRCA1 and BRCA2 genes. BRCA1/2 mutations confer an increased lifetime risk for the development of breast cancer (up to 80%), contralateral breast cancer (about 30% at 10 years), ovarian cancer...
متن کاملIdentification of novel BRCA large genomic rearrangements in Singapore Asian breast and ovarian patients with cancer.
Large genomic rearrangements have been reported to account for about 10-15% of BRCA1 gene mutations. Approximately, 90 BRCA rearrangements have been described to date, all of which but one have been reported in Caucasian populations of predominantly Western European descent. Knowledge of BRCA genomic rearrangements in Asian populations is still largely unknown. In this study, we have investigat...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Value in Health
سال: 2019
ISSN: 1098-3015
DOI: 10.1016/j.jval.2019.09.465